Neurology · Clinical trials
Essential Tremor Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About essential tremor — and why its trials are hard
Essential tremor (ET) is one of the most common movement disorders, characterized by a bilateral, largely symmetric action (postural and kinetic) tremor of the hands and forearms, sometimes involving the head and voice. Though often labeled benign, it can cause substantial disability with writing, eating, drinking, and daily tasks. Pharmacotherapy has scarcely advanced in decades: the two evidence-based first-line agents, propranolol (a nonselective beta-blocker and the main FDA-labeled option) and primidone (an anticonvulsant, used off-label but a mainstay), both predate modern trials and are off-patent. Topiramate has moderate off-label support. Many patients respond incompletely or cannot tolerate side effects, and new drug development has repeatedly disappointed, most recently the Sage/Biogen SAGE-324 program. In refractory cases, device-based therapies dominate innovation: deep brain stimulation (DBS) of the ventral intermediate (VIM) thalamic nucleus and, more recently, MR-guided focused ultrasound (FUS) thalamotomy offer meaningful tremor reduction where medications fail.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Propranolol (Inderal (and generics)) | 1967 (drug approval; long-established labeling for essential/familial tremor) | First-line oral therapy for essential/familial tremor | Multiple older randomized crossover studies (no single modern pivotal trial) | Reduction in tremor amplitude/clinical tremor rating | Roughly 50% reduction in tremor amplitude in many responders; benefit varies widely |
| Primidone (Mysoline (and generics)) | 1954 (approved as anticonvulsant; used off-label as ET mainstay) | First-line/alternative oral therapy, often combined with propranolol | Older randomized controlled trials in ET (off-label use) | Reduction in clinical tremor severity/amplitude | Efficacy comparable to propranolol; substantial early sedation/side effects limit tolerability |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in essential tremor development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| SAGE-324 / BIIB124 (GABA-A PAM) — KINETIC Phase 2 (Sage Therapeutics / Biogen) | Failed to show adequate benefit / program discontinued for essential tremor | Insufficient efficacy margin and dose-limiting CNS side effects (somnolence/dizziness); extended the long drought of new ET drugs |
| Topiramate — Randomized placebo-controlled trials (off-label) | Modest efficacy but frequently limited by cognitive slowing, paresthesias, and weight loss | Tolerability and dropout rates constrained its role to second/third-line therapy |
Choosing the right endpoint
Primary endpoints that matter in essential tremor trials
- Tremor amplitude / accelerometry — Objective quantification of action tremor severity
- The Essential Tremor Rating Assessment Scale (TETRAS) — Modern clinician-rated performance and ADL scale used in device and drug trials
- Fahn-Tolosa-Marin Tremor Rating Scale — Older composite rating scale historically used in ET studies
- Activities of daily living / disability subscales — Capture real-world functional impact (writing, eating, drinking)
- Quality of life (QUEST) — Patient-reported ET-specific quality-of-life measure
How iNGENū runs essential tremor trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Essential Tremor clinical trials — FAQs
What are the first-line drugs for essential tremor?
Why are there so few new drugs for essential tremor?
What options exist if medications don't work?
Ready to discuss your essential tremor trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal